<DOC>
	<DOCNO>NCT02341989</DOCNO>
	<brief_summary>One course adjuvant carboplatin AUC7 consider internationally standard treatment option clinical stage I seminoma , regardless risk factor . Treatment base large , randomized phase III study compare adjuvant carboplatin adjuvant radiotherapy . This study do without register data possible risk factor relapse . The relapse rate follow carboplatin study estimate 5.3 % . Data prospective , risk-adapted Spanish study show patient without risk factor low risk relapse , even without adjuvant treatment . This result also confirm recent analysis SWENOTECA VII data , show group patient risk relapse le 5 % without adjuvant treatment . Combined data SWENOTECA V VII study indicate high risk relapse patient one two risk factor ( tumor 4 cm , stromal invasion rete testis ) treat one course adjuvant carboplatin . The relapse rate group patient 9.4 % , indicate modest effect one course adjuvant carboplatin . If adjuvant chemotherapy prefer treatment strategy , potent chemotherapy regimen explore patient group . The result SWENOTECA III/VI study one course cisplatin-based adjuvant chemotherapy clinical stage I nonseminoma , show low rate relapse . As seminoma even chemosensitive nonseminoma relapse rate follow one course adjuvant BEP expect low , close 1 % . The overall aim investigate whether one course adjuvant BEP low relapse rate one course adjuvant carboplatin AUC7 . In addition , investigate difference health relate quality life well acute long-term toxicity treatment .</brief_summary>
	<brief_title>Adjuvant Bleomycin , Etoposide Cisplatin ( BEP ) Versus Carboplatin Stage I Seminomatous Testicular Cancer</brief_title>
	<detailed_description>Short term overall survival , regardless treatment allocation , expect close 100 % . The primary outcome relapse rate . The power study depend number observed relapse . If relapse rate adjuvant carboplatin group , reference group , low anticipate 9 % , need include patient study . Based previous publish material adjuvant treatment clinical stage I seminoma possible precisely estimate correct relapse rate median follow-up four year . Consequently , estimate relapse rate reference group close end accrual . If estimate relapse rate , thus number relapse , low anticipated increase sample size make sure study meet minimum required number relapse reference group . A possible inclusion study participant compromise Type I error rate study .</detailed_description>
	<mesh_term>Seminoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>Histological diagnosis unilateral seminoma testicular cancer , evaluate size tumor invasion rete testis Clinical stage I Tumor size 4 cm and/or stromal invasion rete testis tumor cell Normal value alphafetoprotein ( AFP ) orchiectomy . A stable , slightly elevate AFP normal value may permit . Age ≥ 18 year &lt; 60 year Adequate organ function define : Serum aspartate transaminase ( ALT ) ≤ 1.5 x upper limit normal ( ULN ) . Total serum bilirubin ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Creatinine clearance &gt; 50 ml/min ( eGFR ) All fertile patient use safe contraception Written inform consent Signs metastatic disease evaluate CT thorax , abdomen pelvis . Patients need restaging ( see SWENOTECA IX ) include Prior diagnosis testicular cancer Chronic pulmonary disorder give high risk bleomycin induce toxicity ( example chronic obstructive pulmonary disease lung fibrosis ) Cancer seminoma testicular cancer Known hypersensitivity contraindication study drug Serious concomitant systemic disorder ( example active infection , unstable cardiovascular disease ) opinion investigator would compromise patient 's ability complete study interfere evaluation efficacy safety study treatment Medical , social , psychological condition could prevent adequate information followup</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chemotherapy , adjuvant</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cisplatin</keyword>
</DOC>